Despite continued macroeconomic headwinds and a cautious investment climate, Mintz’s Venture Capital and Emerging Companies practice remained highly active throughout 2024 and into the first half of 2025. Our team advised on...more
7/31/2025
/ Artificial Intelligence ,
Clinical Trials ,
Cybersecurity ,
Innovation ,
Investment ,
Investors ,
Life Sciences ,
Medical Devices ,
Renewable Energy ,
Software ,
Startups ,
Technology Sector ,
Venture Capital